David H. Gorski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David H. Gorski has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Cecilia L. Speyer
Michael and Marian Ilitch Department of Surgery, Wayne State University School of Medicine, Detroit, USA
3 shared publications- Gretchen L. Gierach
Division of Cancer Epidemiology and Genetics National Cancer Institute Rockville Maryland USA
3 shared publications - Mark E. Sherman
Department of Quantitative Health Sciences, Mayo Clinic College of Medicine, Jacksonville, USA
3 shared publications - Ruth M. Pfeiffer
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA
3 shared publications Ali A. Assi
University of Michigan School of Medicine, M4101 Medical Science Building I — C Wing, 1301 Catherine St., Ann Arbor, MI, 48109-5624, USA
2 shared publicationsAli H. Hachem
Central Michigan University College of Medicine, 1000 Houghton Ave., Saginaw, MI, 48602, USA
2 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by Taylor & Francis in Global Health Action
- Vol. 19 (1) , 2683286
Agreement between seroprevalence- and model-based estimates of COVID-19 burden
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic caused significant global harm. Seroprevalence studies detected antibody increases from SARS-CoV-2 infection, assessing transmission and risk from infection. These studies and epidemiological modeling informed public health policy and behavior. Biases in early seroprevalence analyses caused underestimation of fatality risk, including the risk posed to pediatric populations and to those in lower-income nations. The scope of the pandemic was clarified by seroprevalence studies that better assessed at-risk groups and by adjustment of seroprevalence data for known data biases. Reassessment of seroprevalence data confirms the accuracy of early modeling. Public health authorities should inform the public of this modeling success and of the limitations of early seroprevalence analyses. This will prepare the public to better assess global health risk during future pandemics.
- 9 June 2026
- Published by Taylor & Francis in Global Health Action
- Vol. 19 (1) , 2683286
Open AccessAgreement between seroprevalence- and model-based estimates of COVID-19 burden
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic caused significant global harm. Seroprevalence studies detected antibody increases from SARS-CoV-2 infection, assessing transmission and risk from infection. These studies and epidemiological modeling informed public health policy and behavior. Biases in early seroprevalence analyses caused underestimation of fatality risk, including the risk posed to pediatric populations and to those in lower-income nations. The scope of the pandemic was clarified by seroprevalence studies that better assessed at-risk groups and by adjustment of seroprevalence data for known data biases. Reassessment of seroprevalence data confirms the accuracy of early modeling. Public health authorities should inform the public of this modeling success and of the limitations of early seroprevalence analyses. This will prepare the public to better assess global health risk during future pandemics.
- Open Access
- 21 March 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e64679
Quantifying Public Engagement With Science and Malinformation on COVID-19 Vaccines: Cross-Sectional Study
Background: Medical journals are critical vanguards of research, and previous years have seen increasing public interest in and engagement with medicoscientific findings. How findings propagate and are understood and what harms erroneous claims might cause to public health remain unclear, especially on publicly contentious topics like COVID-19 vaccines. Gauging the engagement of the public with medical science and quantifying propagation patterns of medicoscientific papers are thus important undertakings. In contrast to misinformation and disinformation, which pivot on falsehood, the more nuanced issue of malinformation, where ostensibly true information is presented out of context or selectively curated to cause harm and misconception, has been less researched. As findings and facts can be selectively marshaled to present a misleading picture, it is crucial to consider this issue and its potential ramifications. Objective: This study aims to quantify patterns of public engagement with medical research and the vectors of propagation taken by a high-profile incidence of medical malinformation. Methods: In this work, we undertook an analysis of all altmetric engagements over a decade for 5 leading general-purpose medical journals, constituting approximately 9.8 million engagements with 84,529 papers. We identify and examine the proliferation of sentiment concerning a high-profile publication containing vaccine-negative malinformation. Engagement with this paper, with the highest altmetric score of any paper in an academic journal ever released, was tracked across media outlets worldwide and in social media users on Twitter (subsequently rebranded as X). Vectoring media sources were analyzed, and manual sentiment analysis on high-engagement Twitter shares of the paper was undertaken, contrasted with users’ prior vaccine sentiment. Results: Results of this analysis suggested that this COVID-19 scientific malinformation was much more likely to be engaged and amplified with negative by vaccine-negative Twitter accounts than neutral ones (odds ratio 58.2, 95% CI 9.7-658.0; P<.001), often alluding to the ostensible prestige of medical journals. Malinformation was frequently invoked by conspiracy theory websites and non-news sources (71/181 citations, 39.2%) on the internet to cast doubt on the efficacy of vaccination, many of whom tended to cite the paper repeatedly (51/181, 28.2%). Conclusions: Our findings suggest growing public interest in medical science and present evidence that medical and scientific journals need to be aware of not only the potential overt misinformation but also the more insidious impact of malinformation. Also, we discuss how journals and scientific communicators can reduce the influence of malinformation on public understanding.
- 21 March 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e64679
Open AccessQuantifying Public Engagement With Science and Malinformation on COVID-19 Vaccines: Cross-Sectional Study
Background: Medical journals are critical vanguards of research, and previous years have seen increasing public interest in and engagement with medicoscientific findings. How findings propagate and are understood and what harms erroneous claims might cause to public health remain unclear, especially on publicly contentious topics like COVID-19 vaccines. Gauging the engagement of the public with medical science and quantifying propagation patterns of medicoscientific papers are thus important undertakings. In contrast to misinformation and disinformation, which pivot on falsehood, the more nuanced issue of malinformation, where ostensibly true information is presented out of context or selectively curated to cause harm and misconception, has been less researched. As findings and facts can be selectively marshaled to present a misleading picture, it is crucial to consider this issue and its potential ramifications. Objective: This study aims to quantify patterns of public engagement with medical research and the vectors of propagation taken by a high-profile incidence of medical malinformation. Methods: In this work, we undertook an analysis of all altmetric engagements over a decade for 5 leading general-purpose medical journals, constituting approximately 9.8 million engagements with 84,529 papers. We identify and examine the proliferation of sentiment concerning a high-profile publication containing vaccine-negative malinformation. Engagement with this paper, with the highest altmetric score of any paper in an academic journal ever released, was tracked across media outlets worldwide and in social media users on Twitter (subsequently rebranded as X). Vectoring media sources were analyzed, and manual sentiment analysis on high-engagement Twitter shares of the paper was undertaken, contrasted with users’ prior vaccine sentiment. Results: Results of this analysis suggested that this COVID-19 scientific malinformation was much more likely to be engaged and amplified with negative by vaccine-negative Twitter accounts than neutral ones (odds ratio 58.2, 95% CI 9.7-658.0; P<.001), often alluding to the ostensible prestige of medical journals. Malinformation was frequently invoked by conspiracy theory websites and non-news sources (71/181 citations, 39.2%) on the internet to cast doubt on the efficacy of vaccination, many of whom tended to cite the paper repeatedly (51/181, 28.2%). Conclusions: Our findings suggest growing public interest in medical science and present evidence that medical and scientific journals need to be aware of not only the potential overt misinformation but also the more insidious impact of malinformation. Also, we discuss how journals and scientific communicators can reduce the influence of malinformation on public understanding.
- 12 August 2024
- Published by Taylor & Francis in Infectious Diseases
- Vol. 56 (10) , 897-902
Impact of cross-reactivity and herd immunity on SARS-CoV-2 pandemic severity
Public health systems reported low mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in East Asia, in low-income countries, and for children during the first year of the SARS-CoV-2 pandemic. These reports led commentators to suggest that cross-reactive immunity from prior exposure to other pathogens reduced fatality risk. Resolution of initial infection waves also contributed to speculation that herd immunity prevented further waves prior to vaccination. Serology instead implied that immunity was too limited to achieve herd immunity and that there was little impact from cross-reactive protection. Paediatric deaths exceeded those from influenza, with higher age-specific fatality risk in lower-income nations and similar fatality risk in East Asia compared with demographically similar regions. Neither pre-outbreak exposure to related pathogens nor immunity induced by initial infection waves are necessarily a reliable response to future pathogen outbreaks. Preparedness for future pathogen outbreaks should instead focus on strategies such as voluntary behavioural changes, nonpharmaceutical interventions, and vaccination.
- 12 August 2024
- Published by Taylor & Francis in Infectious Diseases
- Vol. 56 (10) , 897-902
Impact of cross-reactivity and herd immunity on SARS-CoV-2 pandemic severity
Public health systems reported low mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in East Asia, in low-income countries, and for children during the first year of the SARS-CoV-2 pandemic. These reports led commentators to suggest that cross-reactive immunity from prior exposure to other pathogens reduced fatality risk. Resolution of initial infection waves also contributed to speculation that herd immunity prevented further waves prior to vaccination. Serology instead implied that immunity was too limited to achieve herd immunity and that there was little impact from cross-reactive protection. Paediatric deaths exceeded those from influenza, with higher age-specific fatality risk in lower-income nations and similar fatality risk in East Asia compared with demographically similar regions. Neither pre-outbreak exposure to related pathogens nor immunity induced by initial infection waves are necessarily a reliable response to future pathogen outbreaks. Preparedness for future pathogen outbreaks should instead focus on strategies such as voluntary behavioural changes, nonpharmaceutical interventions, and vaccination.
- Open Access
- 23 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Quantifying Public Engagement With Science and Malinformation on COVID-19 Vaccines: Cross-Sectional Study (Preprint)
BACKGROUND Medical journals are critical vanguards of research, and previous years have seen increasing public interest in and engagement with medicoscientific findings. How findings propagate and are understood and what harms erroneous claims might cause to public health remain unclear, especially on publicly contentious topics like COVID-19 vaccines. Gauging the engagement of the public with medical science and quantifying propagation patterns of medicoscientific papers are thus important undertakings. In contrast to misinformation and disinformation, which pivot on falsehood, the more nuanced issue of malinformation, where ostensibly true information is presented out of context or selectively curated to cause harm and misconception, has been less researched. As findings and facts can be selectively marshaled to present a misleading picture, it is crucial to consider this issue and its potential ramifications. OBJECTIVE This study aims to quantify patterns of public engagement with medical research and the vectors of propagation taken by a high-profile incidence of medical malinformation. METHODS In this work, we undertook an analysis of all altmetric engagements over a decade for 5 leading general-purpose medical journals, constituting approximately 9.8 million engagements with 84,529 papers. We identify and examine the proliferation of sentiment concerning a high-profile publication containing vaccine-negative malinformation. Engagement with this paper, with the highest altmetric score of any paper in an academic journal ever released, was tracked across media outlets worldwide and in social media users on Twitter (subsequently rebranded as X). Vectoring media sources were analyzed, and manual sentiment analysis on high-engagement Twitter shares of the paper was undertaken, contrasted with users’ prior vaccine sentiment. RESULTS Results of this analysis suggested that this COVID-19 scientific malinformation was much more likely to be engaged and amplified with negative by vaccine-negative Twitter accounts than neutral ones (odds ratio 58.2, 95% CI 9.7-658.0; P<.001), often alluding to the ostensible prestige of medical journals. Malinformation was frequently invoked by conspiracy theory websites and non-news sources (71/181 citations, 39.2%) on the internet to cast doubt on the efficacy of vaccination, many of whom tended to cite the paper repeatedly (51/181, 28.2%). CONCLUSIONS Our findings suggest growing public interest in medical science and present evidence that medical and scientific journals need to be aware of not only the potential overt misinformation but also the more insidious impact of malinformation. Also, we discuss how journals and scientific communicators can reduce the influence of malinformation on public understanding.
- 23 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessQuantifying Public Engagement With Science and Malinformation on COVID-19 Vaccines: Cross-Sectional Study (Preprint)
BACKGROUND Medical journals are critical vanguards of research, and previous years have seen increasing public interest in and engagement with medicoscientific findings. How findings propagate and are understood and what harms erroneous claims might cause to public health remain unclear, especially on publicly contentious topics like COVID-19 vaccines. Gauging the engagement of the public with medical science and quantifying propagation patterns of medicoscientific papers are thus important undertakings. In contrast to misinformation and disinformation, which pivot on falsehood, the more nuanced issue of malinformation, where ostensibly true information is presented out of context or selectively curated to cause harm and misconception, has been less researched. As findings and facts can be selectively marshaled to present a misleading picture, it is crucial to consider this issue and its potential ramifications. OBJECTIVE This study aims to quantify patterns of public engagement with medical research and the vectors of propagation taken by a high-profile incidence of medical malinformation. METHODS In this work, we undertook an analysis of all altmetric engagements over a decade for 5 leading general-purpose medical journals, constituting approximately 9.8 million engagements with 84,529 papers. We identify and examine the proliferation of sentiment concerning a high-profile publication containing vaccine-negative malinformation. Engagement with this paper, with the highest altmetric score of any paper in an academic journal ever released, was tracked across media outlets worldwide and in social media users on Twitter (subsequently rebranded as X). Vectoring media sources were analyzed, and manual sentiment analysis on high-engagement Twitter shares of the paper was undertaken, contrasted with users’ prior vaccine sentiment. RESULTS Results of this analysis suggested that this COVID-19 scientific malinformation was much more likely to be engaged and amplified with negative by vaccine-negative Twitter accounts than neutral ones (odds ratio 58.2, 95% CI 9.7-658.0; P<.001), often alluding to the ostensible prestige of medical journals. Malinformation was frequently invoked by conspiracy theory websites and non-news sources (71/181 citations, 39.2%) on the internet to cast doubt on the efficacy of vaccination, many of whom tended to cite the paper repeatedly (51/181, 28.2%). CONCLUSIONS Our findings suggest growing public interest in medical science and present evidence that medical and scientific journals need to be aware of not only the potential overt misinformation but also the more insidious impact of malinformation. Also, we discuss how journals and scientific communicators can reduce the influence of malinformation on public understanding.
- Open Access
- 15 March 2023
- Published by Springer Nature in npj Breast Cancer
- Vol. 9 (1) , 1-9
Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy
Although breast density decline with tamoxifen therapy is associated with greater therapeutic benefit, limited data suggest that endocrine symptoms may also be associated with improved breast cancer outcomes. However, it is unknown whether endocrine symptoms are associated with reductions in breast density after tamoxifen initiation. We evaluated treatment-associated endocrine symptoms and breast density change among 74 women prescribed tamoxifen in a 12-month longitudinal study. Treatment-associated endocrine symptoms and sound speed measures of breast density, assessed via novel whole breast ultrasound tomography (m/s), were ascertained before tamoxifen (T0) and at 1–3 (T1), 4–6 (T2), and 12 months (T3) after initiation. CYP2D6 status was genotyped, and tamoxifen metabolites were measured at T3. Using multivariable linear regression, we estimated mean change in breast density by treatment-associated endocrine symptoms adjusting for age, race, menopausal status, body mass index, and baseline density. Significant breast density declines were observed in women with treatment-associated endocrine symptoms (mean change (95% confidence interval) at T1:−0.26 m/s (−2.17,1.65); T2:−2.12 m/s (−4.02,−0.22); T3:−3.73 m/s (−5.82,−1.63); p-trend = 0.004), but not among women without symptoms (p-trend = 0.18) (p-interaction = 0.02). Similar declines were observed with increasing symptom frequency (p-trends for no symptoms = 0.91; low/moderate symptoms = 0.03; high symptoms = 0.004). Density declines remained among women with detectable tamoxifen metabolites or intermediate/efficient CYP2D6 metabolizer status. Emergent/worsening endocrine symptoms are associated with significant, early declines in breast density after tamoxifen initiation. Further studies are needed to assess whether these observations predict clinical outcomes. If confirmed, endocrine symptoms may be a proxy for tamoxifen response and useful for patients and providers to encourage adherence.
- 15 March 2023
- Published by Springer Nature in npj Breast Cancer
- Vol. 9 (1) , 1-9
Open AccessShort-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy
Although breast density decline with tamoxifen therapy is associated with greater therapeutic benefit, limited data suggest that endocrine symptoms may also be associated with improved breast cancer outcomes. However, it is unknown whether endocrine symptoms are associated with reductions in breast density after tamoxifen initiation. We evaluated treatment-associated endocrine symptoms and breast density change among 74 women prescribed tamoxifen in a 12-month longitudinal study. Treatment-associated endocrine symptoms and sound speed measures of breast density, assessed via novel whole breast ultrasound tomography (m/s), were ascertained before tamoxifen (T0) and at 1–3 (T1), 4–6 (T2), and 12 months (T3) after initiation. CYP2D6 status was genotyped, and tamoxifen metabolites were measured at T3. Using multivariable linear regression, we estimated mean change in breast density by treatment-associated endocrine symptoms adjusting for age, race, menopausal status, body mass index, and baseline density. Significant breast density declines were observed in women with treatment-associated endocrine symptoms (mean change (95% confidence interval) at T1:−0.26 m/s (−2.17,1.65); T2:−2.12 m/s (−4.02,−0.22); T3:−3.73 m/s (−5.82,−1.63); p-trend = 0.004), but not among women without symptoms (p-trend = 0.18) (p-interaction = 0.02). Similar declines were observed with increasing symptom frequency (p-trends for no symptoms = 0.91; low/moderate symptoms = 0.03; high symptoms = 0.004). Density declines remained among women with detectable tamoxifen metabolites or intermediate/efficient CYP2D6 metabolizer status. Emergent/worsening endocrine symptoms are associated with significant, early declines in breast density after tamoxifen initiation. Further studies are needed to assess whether these observations predict clinical outcomes. If confirmed, endocrine symptoms may be a proxy for tamoxifen response and useful for patients and providers to encourage adherence.
- Open Access
- 1 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (3) , 792
Rapid Reductions in Breast Density following Tamoxifen Therapy as Evaluated by Whole-Breast Ultrasound Tomography
Purpose: Women whose mammographic breast density declines within 12–18 months of initiating tamoxifen for chemoprevention or adjuvant treatment show improved therapeutic responses compared with those whose density is unchanged. We tested whether measuring changes in sound speed (a surrogate of breast density) using ultrasound tomography (UST) could enable rapid identification of favorable responses to tamoxifen. Methods: We evaluated serial density measures at baseline and at 1 to 3, 4 to 6, and 12+ months among 74 women (aged 30–70 years) following initiation of tamoxifen for clinical indications, including an elevated risk of breast cancer (20%) and diagnoses of in situ (39%) or invasive (40%) breast carcinoma, enrolled at Karmanos Cancer Institute and Henry Ford Health System (Detroit, MI, USA). For comparison, we evaluated an untreated group with screen negative mammography and frequency-matched on age, race, and menopausal status (n = 150), at baseline and 12 months. Paired t-tests were used to assess differences in UST sound speed over time and between tamoxifen-treated and untreated patients. Results: Sound speed declined steadily over the 12 month period among patients receiving tamoxifen (mean (SD): −3.0 (8.2) m/s; p = 0.001), whereas density remained unchanged in the untreated group (mean (SD): 0.4 (7.1) m/s; p = 0.75 (relative change between groups: p = 0.0009)). In the tamoxifen group, we observed significant sound speed reductions as early as 4–6 months after tamoxifen initiation (mean (SD): −2.1 (6.8) m/s; p = 0.008). Sound speed reductions were greatest among premenopausal patients (P-interaction = 0.0002) and those in the middle and upper tertiles of baseline sound speed (P-interaction = 0.002). Conclusions: UST can image rapid declines in sound speed following initiation of tamoxifen. Given that sound speed and mammographic density are correlated, we propose that UST breast imaging may capture early responses to tamoxifen, which in turn may have utility in predicting therapeutic efficacy.
- 1 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (3) , 792
Open AccessRapid Reductions in Breast Density following Tamoxifen Therapy as Evaluated by Whole-Breast Ultrasound Tomography
Purpose: Women whose mammographic breast density declines within 12–18 months of initiating tamoxifen for chemoprevention or adjuvant treatment show improved therapeutic responses compared with those whose density is unchanged. We tested whether measuring changes in sound speed (a surrogate of breast density) using ultrasound tomography (UST) could enable rapid identification of favorable responses to tamoxifen. Methods: We evaluated serial density measures at baseline and at 1 to 3, 4 to 6, and 12+ months among 74 women (aged 30–70 years) following initiation of tamoxifen for clinical indications, including an elevated risk of breast cancer (20%) and diagnoses of in situ (39%) or invasive (40%) breast carcinoma, enrolled at Karmanos Cancer Institute and Henry Ford Health System (Detroit, MI, USA). For comparison, we evaluated an untreated group with screen negative mammography and frequency-matched on age, race, and menopausal status (n = 150), at baseline and 12 months. Paired t-tests were used to assess differences in UST sound speed over time and between tamoxifen-treated and untreated patients. Results: Sound speed declined steadily over the 12 month period among patients receiving tamoxifen (mean (SD): −3.0 (8.2) m/s; p = 0.001), whereas density remained unchanged in the untreated group (mean (SD): 0.4 (7.1) m/s; p = 0.75 (relative change between groups: p = 0.0009)). In the tamoxifen group, we observed significant sound speed reductions as early as 4–6 months after tamoxifen initiation (mean (SD): −2.1 (6.8) m/s; p = 0.008). Sound speed reductions were greatest among premenopausal patients (P-interaction = 0.0002) and those in the middle and upper tertiles of baseline sound speed (P-interaction = 0.002). Conclusions: UST can image rapid declines in sound speed following initiation of tamoxifen. Given that sound speed and mammographic density are correlated, we propose that UST breast imaging may capture early responses to tamoxifen, which in turn may have utility in predicting therapeutic efficacy.
- 1 December 2020
- Published by Springer Nature in Theoretical Medicine and Bioethics
- Vol. 41 (5-6) , 223-237
The ethics of innovation for Alzheimer’s disease: the risk of overstating evidence for metabolic enhancement protocols
Medical practice is ideally based on robust, relevant research. However, the lack of disease-modifying treatments for Alzheimer’s disease has motivated “innovative practice” to improve patients’ well-being despite insufficient evidence for the regular use of such interventions in health systems treating millions of patients. Innovative or new non-validated practice poses at least three distinct ethical questions: first, about the responsible application of new non-validated practice to individual patients (clinical ethics); second, about the way in which data from new non-validated practice are communicated via the scientific and lay press (scientific communication ethics); and third, about the prospect of making new non-validated interventions widely available before more definitive testing (public health ethics). We argue that the authors of metabolic enhancement protocols for Alzheimer’s disease have overstated the evidence in favor of these interventions within the scientific and lay press, failing to communicate weaknesses in their data and uncertainty about their conclusions. Such unmeasured language may create false hope, cause financial harm, undermine informed consent, and frustrate the production of generalizable knowledge necessary to face the societal problems posed by this devastating disease. We therefore offer more stringent guidelines for responsible innovation in the treatment of Alzheimer’s disease.
- 1 December 2020
- Published by Springer Nature in Theoretical Medicine and Bioethics
- Vol. 41 (5-6) , 223-237
The ethics of innovation for Alzheimer’s disease: the risk of overstating evidence for metabolic enhancement protocols
Medical practice is ideally based on robust, relevant research. However, the lack of disease-modifying treatments for Alzheimer’s disease has motivated “innovative practice” to improve patients’ well-being despite insufficient evidence for the regular use of such interventions in health systems treating millions of patients. Innovative or new non-validated practice poses at least three distinct ethical questions: first, about the responsible application of new non-validated practice to individual patients (clinical ethics); second, about the way in which data from new non-validated practice are communicated via the scientific and lay press (scientific communication ethics); and third, about the prospect of making new non-validated interventions widely available before more definitive testing (public health ethics). We argue that the authors of metabolic enhancement protocols for Alzheimer’s disease have overstated the evidence in favor of these interventions within the scientific and lay press, failing to communicate weaknesses in their data and uncertainty about their conclusions. Such unmeasured language may create false hope, cause financial harm, undermine informed consent, and frustrate the production of generalizable knowledge necessary to face the societal problems posed by this devastating disease. We therefore offer more stringent guidelines for responsible innovation in the treatment of Alzheimer’s disease.
- Open Access
- 29 January 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (2) , 367
Using Whole Breast Ultrasound Tomography to Improve Breast Cancer Risk Assessment: A Novel Risk Factor Based on the Quantitative Tissue Property of Sound Speed
Mammographic percent density (MPD) is an independent risk factor for developing breast cancer, but its inclusion in clinical risk models provides only modest improvements in individualized risk prediction, and MPD is not typically assessed in younger women because of ionizing radiation concerns. Previous studies have shown that tissue sound speed, derived from whole breast ultrasound tomography (UST), a non-ionizing modality, is a potential surrogate marker of breast density, but prior to this study, sound speed has not been directly linked to breast cancer risk. To that end, we explored the relation of sound speed and MPD with breast cancer risk in a case-control study, including 61 cases with recent breast cancer diagnoses and a comparison group of 165 women, frequency matched to cases on age, race, and menopausal status, and with a recent negative mammogram and no personal history of breast cancer. Multivariable odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for the relation of quartiles of MPD and sound speed with breast cancer risk adjusted for matching factors. Elevated MPD was associated with increased breast cancer risk, although the trend did not reach statistical significance (OR per quartile = 1.27, 95% CI: 0.95, 1.70; ptrend = 0.10). In contrast, elevated sound speed was significantly associated with breast cancer risk in a dose–response fashion (OR per quartile = 1.83, 95% CI: 1.32, 2.54; ptrend = 0.0003). The OR trend for sound speed was statistically significantly different from that observed for MPD (p = 0.005). These findings suggest that whole breast sound speed may be more strongly associated with breast cancer risk than MPD and offer future opportunities for refining the magnitude and precision of risk associations in larger, population-based studies, including women younger than usual screening ages.
- 29 January 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (2) , 367
Open AccessUsing Whole Breast Ultrasound Tomography to Improve Breast Cancer Risk Assessment: A Novel Risk Factor Based on the Quantitative Tissue Property of Sound Speed
Mammographic percent density (MPD) is an independent risk factor for developing breast cancer, but its inclusion in clinical risk models provides only modest improvements in individualized risk prediction, and MPD is not typically assessed in younger women because of ionizing radiation concerns. Previous studies have shown that tissue sound speed, derived from whole breast ultrasound tomography (UST), a non-ionizing modality, is a potential surrogate marker of breast density, but prior to this study, sound speed has not been directly linked to breast cancer risk. To that end, we explored the relation of sound speed and MPD with breast cancer risk in a case-control study, including 61 cases with recent breast cancer diagnoses and a comparison group of 165 women, frequency matched to cases on age, race, and menopausal status, and with a recent negative mammogram and no personal history of breast cancer. Multivariable odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for the relation of quartiles of MPD and sound speed with breast cancer risk adjusted for matching factors. Elevated MPD was associated with increased breast cancer risk, although the trend did not reach statistical significance (OR per quartile = 1.27, 95% CI: 0.95, 1.70; ptrend = 0.10). In contrast, elevated sound speed was significantly associated with breast cancer risk in a dose–response fashion (OR per quartile = 1.83, 95% CI: 1.32, 2.54; ptrend = 0.0003). The OR trend for sound speed was statistically significantly different from that observed for MPD (p = 0.005). These findings suggest that whole breast sound speed may be more strongly associated with breast cancer risk than MPD and offer future opportunities for refining the magnitude and precision of risk associations in larger, population-based studies, including women younger than usual screening ages.
- 5 March 2019
- Published by Springer Nature
- p. 95-112
Cancer Quackery and Fake News: Targeting the Most Vulnerable
- 5 March 2019
- Published by Springer Nature
- p. 95-112
Cancer Quackery and Fake News: Targeting the Most Vulnerable